About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Erythropoietin Resistance in Anemia of Chronic Kidney Disease

NCT00526747·2 sites·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

Duke University

Age

18–any

Sex

ALL

Healthy volunteers

Not accepted

You may be eligible if

prevalent patients greater than or equal to 18 years old with CKD defined as a glomerular filtration rate \< 60 cc/min

You may not be if

active GI bleeding or history of GI bleed in the prior 3 months
uncontrolled hyperparathyroidism (PTH\>500)
untreated iron deficiency (transferrin saturation \< 20% and ferritin \< 100
overt infection
active hemolysis
hemoglobinopathies
known adverse response to erythropoietin
prior kidney transplant
aluminum toxicity

The record

StatusCompleted

PhaseNo phase

Taking part32

StartedAug 2007

UpdatedApr 11, 2013

Conditions

Anemia Kidney Failure Erythropoietin

Where2

Durham Nephrology Anemia Clinic
Durham, North Carolina, United States
Duke University Medical Center Anemia Clinic
Durham, North Carolina, United States

Clareo Health | Erythropoietin Resistance in Anemia of Chronic Kidney Disease